24 August 2021
Where suitable, TGA inspectors will undertake remote and/or hybrid Good Manufacturing Practice (GMP) domestic inspections during the COVID-19 pandemic.
9 March 2021
Due to the unprecedented pressures COVID-19 has placed on the pharmaceutical industry, sponsors of listed medicines and registered over-the-counter (OTC) and complementary medicines (RCM) are eligible to request consent not to comply with TGO 92 labelling requirements for a limited time.
3 August 2020
Information on advertising of products related to COVID-19, GMP information for sponsors and manufacturers and access to coronavirus tests, medicines and vaccines, including medicine shortages
10 July 2020
The TGA has granted provisional approval to remdesivir ("Veklury", Gilead Sciences Pty Ltd) as the first treatment option for COVID-19.
3 June 2020
New modelling demonstrates that supply of critical medicines for ventilating patients supports a return to elective surgery.
8 May 2020
Consumers should be alert to misleading claims made online about Miracle Mineral Solution (MMS). The TGA has not approved MMS for use to treat, cure, prevent or alleviate any disease or condition.
28 April 2020
Advice for faecal microbiota transplant (FMT) providers on safety protections related to COVID-19.
31 March 2020
Clarification about the clinical trial process as it relates to COVID-19
27 March 2020
A change in process has been implemented to facilitate batch release of biological medicines during the COVID-19 pandemic
19 March 2020
Information for manufacturers of therapeutic goods about the suspension of all overseas GMP (Good Manufacturing Practice) inspections and QMS (Quality Management System) audits